CStone Pharmaceuticals and Istituto Gentili Enter into European Commercialization Collaboration
July 14, 2025
Source: drugdu
52
Recently , CStone Pharmaceuticals announced that it has reached an exclusive strategic cooperation with Istituto Gentili (hereinafter referred to as Gentili) on the commercialization of Sugemalimab in Western Europe and the United Kingdom. Gentili has obtained the exclusive commercialization rights of Sugemalimab in 23 countries, and CStone Pharmaceuticals will receive a payment of up to US$192.5 million, including an initial payment, registration and sales milestone payments, and a revenue share of nearly 50% of the net sales of Sugemalimab in the authorized area.
This cooperation shows that CStone Pharmaceuticals' products have been recognized in the international market, which will help enhance its influence in the field of global cancer treatment. In the long run, this cooperation will enhance investors' confidence in the company's future growth and lay the foundation for the company to further expand its overseas market.
https://www.nbd.com.cn/articles/2025-07-08/3936641.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- CureVac reaches settlement with BioNTech, Pfizer over COVID-19 vaccine patents August 9, 2025
- New progress in AIDS vaccine research and development! Vaccines may usher in new opportunities August 9, 2025
- Bio-thera receives approval for clinical trials of BAT1308 and other drugs August 9, 2025
- FDA approves Tongxin Medical’s BrioVAD to enter confirmatory clinical study August 9, 2025
- Fosun Pharma’s HLX43 for injection receives approval from the U.S. FDA for clinical trials August 9, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
